0001661181-19-000006.txt : 20190905
0001661181-19-000006.hdr.sgml : 20190905
20190905201117
ACCESSION NUMBER: 0001661181-19-000006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190903
FILED AS OF DATE: 20190905
DATE AS OF CHANGE: 20190905
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NUSSDORF GLENN H
CENTRAL INDEX KEY: 0001244191
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37906
FILM NUMBER: 191078324
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wisdom Starr
CENTRAL INDEX KEY: 0001760694
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37906
FILM NUMBER: 191078325
MAIL ADDRESS:
STREET 1: C/O ORGANOGENESIS INC.
STREET 2: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Organogenesis Holdings Inc.
CENTRAL INDEX KEY: 0001661181
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
BUSINESS PHONE: 781-575-0775
MAIL ADDRESS:
STREET 1: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
FORMER COMPANY:
FORMER CONFORMED NAME: Avista Healthcare Public Acquisition Corp.
DATE OF NAME CHANGE: 20151215
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2019-09-03
0001661181
Organogenesis Holdings Inc.
ORGO
0001244191
NUSSDORF GLENN H
35 SAWGRASS DRIVE
BELLPORT
NY
11713
1
0
1
0
0001760694
Wisdom Starr
44 WILSON STREET
HARTSDALE
NY
10530
0
0
1
0
Class A Common Stock
2019-09-03
4
P
0
50000
4.3786
A
67896723
D
Class A Common Stock
2019-09-03
4
P
0
100
4.25
A
67896823
D
Class A Common Stock
2019-09-04
4
P
0
50000
4.6238
A
67946823
D
Class A Common Stock
2019-09-05
4
P
0
5000
4.5328
A
67951823
D
The reported securities were purchased and are held directly by Glenn H. Nussdorf, who is a member of the Group (as defined below).
The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $4.28 to $4.48, inclusive. The reporting person undertakes to provide to Organogenesis Holdings Inc. ("ORGO"), any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
The reported securities were purchased and are held directly by Dennis Erani, who is a member of the Group.
The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $4.37 to $4.92, inclusive. The reporting person undertakes to provide to ORGO, any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4.
The reported securities were purchased and are held directly by Albert Erani, who is a member of the Group.
The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $4.52 to $4.55, inclusive. The reporting person undertakes to provide to ORGO, any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (6) to this Form 4.
Alan A. Ades, Albert Erani, Glenn H. Nussdorf, Dennis Erani, Starr Wisdom and certain of their respective affiliates, including Organo PFG LLC, Organo Investors LLC, Dennis Erani 2012 Issue Trust, Alan Ades as Trustee of the Alan Ades 2014 GRAT, Albert Erani Family Trust dated 12/29/2012, GN 2016 Family Trust u/a/d August 12, 2016 and GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016, referred to collectively as the "Controlling Entities", are parties to a Controlling Stockholders' Agreement dated December 10, 2018 with Organogenesis Holdings Inc. (the "Stockholders' Agreement"). The Stockholders' Agreement, among other things, provides for nomination rights of the Controlling Entities with respect to four directors of the Issuer and qualifies the Issuer as a "controlled company" under the Nasdaq listing rules. As a result of the Stockholders' Agreement, the reporting persons may be deemed to be members of a group (the "Group") holding over 10% of the outstanding shares of common stock of the issuer for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended.
This is Form 4 No. 2 of 2 filed for the Controlling Entities.
/s/ Stacie S. Aarestad, Attorney-in-Fact
2019-09-05